Bußmann C, Novak N
Klinik und Poliklinik für Dermatologie und Allergologie, Universität Bonn, Germany.
N. Novak is being supported by a DFG NO454/5-2 Heisenberg professorship.
Allergol Select. 2017 Aug 4;1(1):1-8. doi: 10.5414/ALX01285E. eCollection 2017.
Therapy of severe atopic dermatitis, which is refractory to consistent treatment with topical steroids and topical calcineurin inhibitors is still a problem in many cases. The use of cyclosporine, which is the only approved systemic drug for the therapy of severe atopic dermatitis, is often limited by contraindications or adverse reactions. In this context, results from controlled and open-label studies with novel therapeutic approaches such as methotrexate, omalizumab or rituximab, which are in part very promising, are of great interest. In this work we would like to provide an overview of established and new therapeutic options for the treatment of severe atopic dermatitis.
对于严重特应性皮炎患者,若持续使用外用类固醇和外用钙调神经磷酸酶抑制剂治疗无效,在很多情况下仍是个难题。环孢素是唯一获批用于治疗严重特应性皮炎的全身性药物,但其使用常因禁忌证或不良反应而受限。在这一背景下,甲氨蝶呤、奥马珠单抗或利妥昔单抗等新型治疗方法的对照研究和开放标签研究结果(部分结果很有前景)备受关注。在本文中,我们将概述治疗严重特应性皮炎的既有治疗方案和新的治疗选择。